2015
DOI: 10.1007/s12272-015-0571-1
|View full text |Cite
|
Sign up to set email alerts
|

Histone deacetylase inhibitors in hematological malignancies and solid tumors

Abstract: Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs. Because aberrant activity and expression of HDACs have been implicated in various cancer types, a wide range of HDAC inhibitors are being investigated as anticancer agents. Furthermore, due to the demonstrable anticancer activity in both in vitro and in vivo studies, numerous HDAC inhibitors have undergone a rapid phase of clinical development in various cancer types, either as a monotherapy or in combination with other anticance… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
93
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 114 publications
(94 citation statements)
references
References 147 publications
1
93
0
Order By: Relevance
“…Since HDACs are a diverse group of proteins, we hypothesise that a better understanding of the expression of specific HDACs in human uveal melanoma tissue will lead to a more nuanced and targeted understanding of the roles they play in this devastating disease. Herewith we present immunohistochemical data on the expression of six HDACs (HDAC1, HDAC2, HDAC3, HDAC4, HDAC6 and SIRT2), chosen for their known association with prognosis, grade and stage in other malignancies [13,24,25].…”
Section: Introductionmentioning
confidence: 99%
“…Since HDACs are a diverse group of proteins, we hypothesise that a better understanding of the expression of specific HDACs in human uveal melanoma tissue will lead to a more nuanced and targeted understanding of the roles they play in this devastating disease. Herewith we present immunohistochemical data on the expression of six HDACs (HDAC1, HDAC2, HDAC3, HDAC4, HDAC6 and SIRT2), chosen for their known association with prognosis, grade and stage in other malignancies [13,24,25].…”
Section: Introductionmentioning
confidence: 99%
“…Romidepsin occupies second rank and has been approved for CTCL on November 2009 and for peripheral T-cell lymphoma (PTCL) on May 2011. Belinostat was the third inhibitor approved for treating relapsed/refractory PTCL on July 2014 (Ververis et al 2013;Chun 2015). Panobinostat the last and fourth HDACi gained approval on 23 February 2015 against multiple myeloma (MM) ( Table 2) (Ganai 2016)…”
Section: Classification Of Hdacimentioning
confidence: 99%
“…[2][3][4] Despite promising results in the treatment of hematological disorders, there is a need to improve the efficacy of these drugs in the clinic. 5 One way for such improvement is the development of more specific inhibitor directed against individual HDAC. By targeting one of the most relevant HDAC members critically involved in tumor progression, it may be possible to greatly improve the efficacy with the additional advantage of removing certain toxicities that may be associated with the inhibition of multiple HDAC.…”
Section: Introductionmentioning
confidence: 99%